SONN - Sonnet BioTherapeutics Holdings, Inc. Stock Analysis | Stock Taper
Logo

About Sonnet BioTherapeutics Holdings, Inc.

https://www.sonnetbio.com

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.

Raghu Rao

CEO

Raghu Rao

Compensation Summary
(Year 2024)

Salary $538,998
Stock Awards $87,628
Total Compensation $626,626
Industry Biotechnology
Sector Healthcare
Went public October 31, 2006
Method of going public IPO
Full time employees 13

Split Record

Date Type Ratio
2024-09-30 Reverse 1:8
2023-09-01 Reverse 1:22

ETFs Holding This Stock

Summary

Total 1

Showing Top 1 of 1

Most Recent Analyst Grades

Grade Summary

Buy 1

Showing Top 1 of 1

Price Target

Target High $0
Target Low $0
Target Median $0
Target Consensus $0

Institutional Ownership